Drugs / JCXH-211
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06468605 | Nov 2025 → Oct 2027 | malignant glioma | Duke University | Withdrawn | No outcome recorded |
| Phase 1 | NCT05727839 | Feb 2023 → Sep 2024 | cancer, skin neoplasm | Immorna Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05539157 | Oct 2022 → Mar 2024 | cancer, skin neoplasm | Immorna Biotherapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06781125 | Mar 2026 → Mar 2028 expected | cancer | Immorna Biotherapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JCXH-211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06468605 ↗ |
| Modality | Other / unclassified | “The study drug JCXH-211, is an immunotherapy drug.” NCT05539157 ↗ |
| Route | Other | “JCXH-211 Intratumoral Injection” NCT05539157 ↗ |